Viatris (FRA:VIA) Forward PE Ratio : 4.21 (As of May. 03, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Viatris Forward PE Ratio?

Viatris's Forward PE Ratio for today is 4.21.

Viatris's PE Ratio without NRI for today is 57.86.

Viatris's PE Ratio for today is 290.75.

Viatris Forward PE Ratio Historical Data

The historical data trend for Viatris's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Forward PE Ratio Chart

Viatris Annual Data

Trend

2015-12

2016-12

2017-12

2018-12

2019-12

2020-12

2021-12

2022-12

2023-12

2024-04

Forward PE Ratio

11.06

6.99

7.81

5.31

4.48

4.34

3.47

3.48

3.76

4.19

Viatris Quarterly Data
	2015-12	2016-03	2016-06	2016-09	2016-12	2017-03	2017-06	2017-09	2017-12	2018-03	2018-06	2018-09	2018-12	2019-03	2019-06	2019-09	2019-12	2020-03	2020-06	2020-09	2020-12	2021-03	2021-06	2021-09	2021-12	2022-03	2022-06	2022-09	2022-12	2023-03	2023-06	2023-09	2023-12	2024-03
Forward PE Ratio	11.06	7.75	9.27	6.65	6.99	7.41	7.39	5.99	7.81	7.46	6.79	6.95	5.31	6.27	4.44	4.51	4.48	3.46	3.75	3.02	4.34	4.36	4.30	3.58	3.47	3.13	3.16	2.62	3.48	3.36	3.43	3.49	3.76	4.33

Competitive Comparison of Viatris's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Viatris's Forward PE Ratio falls into.

Viatris Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Viatris (FRA:VIA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Viatris Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Viatris's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (FRA:VIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (FRA:VIA) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.